

Xian-De Liu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7007777/publications.pdf>

Version: 2024-02-01

13
papers

5,346
citations

840776

11
h-index

1058476

14
g-index

15
all docs

15
docs citations

15
times ranked

14672
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 1475.	3.7	10
2	PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. <i>Nature Communications</i> , 2020, 11, 2135.	12.8	114
3	Macrophage HIF-1 α Is an Independent Prognostic Indicator in Kidney Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4970-4982.	7.0	45
4	miR-200c inhibits TGF- β -induced-EMT to restore trastuzumab sensitivity by targeting ZEB1 and ZEB2 in gastric cancer. <i>Cancer Gene Therapy</i> , 2018, 25, 68-76.	4.6	70
5	VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. <i>Science</i> , 2018, 361, 290-295.	12.6	134
6	HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas. <i>Cancer Research</i> , 2017, 77, 5313-5326.	0.9	19
7	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	9.1	4,701
8	Autophagy degrades hypoxia inducible factors. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1104428.	0.7	12
9	Fast clearance of lipid droplets through MAP1S-activated autophagy suppresses clear cell renal cell carcinomas and promotes patient survival. <i>Oncotarget</i> , 2016, 7, 6255-6265.	1.8	40
10	The impact of FGFR1 and FRS2 α expression on sorafenib treatment in metastatic renal cell carcinoma. <i>BMC Cancer</i> , 2015, 15, 304.	2.6	16
11	Dysregulation of HIF2 α and autophagy in renal cell carcinoma. <i>Molecular and Cellular Oncology</i> , 2015, 2, e965643.	0.7	3
12	Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2015, 3, 1017-1029.	3.4	159
13	Genetic and Pharmacological Strategies to Refunctionalize the von Hippel Lindau R167Q Mutant Protein. <i>Cancer Research</i> , 2014, 74, 3127-3136.	0.9	20